Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nogapendekin alfa inbakicept + Bacillus Calmette-Guerin
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravesical
01
Overview
Nogapendekin alfa inbakicept + Bacillus Calmette-Guerin is a **fixed-dose combination medication** used for adults with **BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ**, with or without papillary tumors[1][4][6]. It combines nogapendekin alfa (a human IL-15N72D variant with enhanced activity and stability), inbakicept (an interleukin-15 receptor alpha subunit fused to IgG1 Fc), and Bacillus Calmette-Guerin. The core mechanism is potent **interleukin-15 receptor agonism**, which stimulates **CD8+ memory T cells** and **natural killer cells** in the bladder, enhancing local immune responses and synergizing with BCG's immunostimulatory anti-tumor effects[1][2][6]. Induction and maintenance therapy are administered by intravesical instillation.
- Brand names
- Anktiva (for N-803)
- Other names
- nogapendekin alfa inbakicept-pmlnnogapendekin alfa-inbakicept-Bacillus Calmette-GuerinN-803 + BCG
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL2RG (Interleukin-2 receptor gamma subunit)IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on nogapendekin alfa inbakicept + Bacillus Calmette-Guerin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nogapendekin alfa inbakicept + Bacillus Calmette-Guerin.